Display options
Cite
Muller L, Muller-Haegele S, Mitsuhashi M, et al. Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology. 2015;4(6):e1008347doi: 10.1080/2162402X.2015.1008347.
Muller, L., Muller-Haegele, S., Mitsuhashi, M., Gooding, W., Okada, H., & Whiteside, T. L. (2015). Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology, 4(6), e1008347. https://doi.org/10.1080/2162402X.2015.1008347
Muller, Laurent, et al. "Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival." Oncoimmunology vol. 4,6 (2015): e1008347. doi: https://doi.org/10.1080/2162402X.2015.1008347
Muller L, Muller-Haegele S, Mitsuhashi M, Gooding W, Okada H, Whiteside TL. Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology. 2015 Mar 02;4(6):e1008347. doi: 10.1080/2162402X.2015.1008347. eCollection 2015 Jun. PMID: 26155415; PMCID: PMC4485717.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Mar 02;4(6):e1008347. doi: 10.1080/2162402X.2015.1008347. eCollection 2015 Jun.

Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival.

Oncoimmunology

Laurent Muller, Sylvia Muller-Haegele, Masato Mitsuhashi, William Gooding, Hideho Okada, Theresa L Whiteside

Affiliations

  1. University of Pittsburgh Cancer Institute ; Pittsburgh, PA, USA ; Department of Otolaryngology and Head & Neck Surgery; University Hospital Basel ; Basel, Switzerland.
  2. University of Pittsburgh Cancer Institute ; Pittsburgh, PA, USA.
  3. Hitachi Chemical Research Center, Inc. ; Irvine, CA, USA.
  4. University of Pittsburgh Cancer Institute ; Pittsburgh, PA, USA ; Departments of Neurological Surgery; Surgery and Immunology; University of Pittsburgh School of Medicine ; Pittsburgh, PA, USA.
  5. University of Pittsburgh Cancer Institute ; Pittsburgh, PA, USA ; Departments of Pathology; Immunology and Otolaryngology; University of Pittsburgh School of Medicine ; Pittsburgh, PA, USA.

PMID: 26155415 PMCID: PMC4485717 DOI: 10.1080/2162402X.2015.1008347

Abstract

Exosomes in plasma of glioma patients hold promise as biomarkers of prognosis. We aimed to determine whether changes in total exosomal protein and mRNA expression levels could serve as surrogate markers of immunological and clinical responses in glioma patients receiving antitumor vaccines. Exosomes were isolated from pre/post-vaccine plasma specimens in 20/22 patients enrolled in a phase I/II trial with the antitumor vaccine. Exosomal protein content was analyzed and mRNA expression levels for 24 genes were simultaneously assessed by qRT-PCR. Pre- to post-vaccination changes in exosomal protein and ΔCt values were correlated with immunological and clinical responses and survival using Spearman rank statistics and hazard ratios (HR). Exosomal protein levels positively correlated (

Keywords: AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; ATP, adenosine triphosphates; EV, extracellular vesicles; GAA, glioma associated antigens; GBM, glioblastoma multiforme; MRI, magnetic resonance imaging; NC, normal controls; OS, overall survival; PD-1, programmed death-1; PD-L1, programmed death ligand 1; TEM, transmission electron microscopy; TEX, tumor-derived exosomes; TTP, time to progression; glioma; mRNA; plasma-derived exosomes; survival; vaccination

References

  1. Tumour Biol. 2014 Sep;35(9):8425-38 - PubMed
  2. J Immunol Methods. 2014 Sep;411:55-65 - PubMed
  3. Neuro Oncol. 2005 Apr;7(2):122-33 - PubMed
  4. Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7312-7 - PubMed
  5. J Cell Biol. 2013 Feb 18;200(4):373-83 - PubMed
  6. Biochem Pharmacol. 2011 May 15;81(10):1171-82 - PubMed
  7. Pharmgenomics Pers Med. 2014 Feb 13;7:65-77 - PubMed
  8. Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22 - PubMed
  9. Nat Med. 2012 Jun;18(6):883-91 - PubMed
  10. Biochem Soc Trans. 2013 Feb 1;41(1):245-51 - PubMed
  11. Front Physiol. 2012 Jul 24;3:294 - PubMed
  12. Cancer Biomark. 2014;14 (2-3):185-94 - PubMed
  13. PLoS One. 2012;7(10):e46737 - PubMed
  14. Neuro Oncol. 2014 Apr;16(4):520-7 - PubMed
  15. J Neurooncol. 2009 Oct;95(1):117-28 - PubMed
  16. Haematologica. 2011 Sep;96(9):1302-9 - PubMed
  17. BMC Cancer. 2012 Jan 17;12:22 - PubMed
  18. Target Oncol. 2015 Mar;10(1):1-14 - PubMed
  19. Nat Med. 2012 Dec;18(12):1835-40 - PubMed
  20. J Immunol Methods. 2010 Dec 15;363(1):95-100 - PubMed
  21. Pharmacol Rev. 2012 Jul;64(3):676-705 - PubMed
  22. Clin Chem. 2014 Apr;60(4):675-82 - PubMed
  23. RNA Biol. 2013 Aug;10(8):1333-44 - PubMed
  24. Front Immunol. 2014 Apr 10;5:160 - PubMed
  25. Cancer Res. 1992 Aug 15;52(16):4297-305 - PubMed
  26. Front Genet. 2013 Jul 30;4:142 - PubMed
  27. Semin Immunopathol. 2011 Sep;33(5):419-40 - PubMed
  28. Int J Mol Sci. 2013 Mar 06;14(3):5338-66 - PubMed
  29. FASEB J. 2009 May;23(5):1541-57 - PubMed
  30. Nat Cell Biol. 2008 Dec;10(12):1470-6 - PubMed
  31. Neuro Oncol. 2011 Jan;13(1):99-108 - PubMed
  32. Trends Cell Biol. 2009 Feb;19(2):43-51 - PubMed
  33. J Clin Oncol. 2011 Jan 20;29(3):330-6 - PubMed
  34. Cell Mol Life Sci. 2011 Aug;68(16):2667-88 - PubMed
  35. Biochem Biophys Res Commun. 2014 Jan 17;443(3):1066-72 - PubMed

Publication Types

Grant support